Skip to main content

Table 1 Description of studies providing data on FEV1 and SGRQ, dyspnoea (TDI), or exacerbations for long-acting bronchodilators

From: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review

Study

Duration, (months)*

Number randomised (by treatment)

Age, (years)

Male, (%)

Smoking history, (pack years)

FEV1 % predicted

Outcomes reported

       

SGRQ total

SGRQ domains

Number with ≥ 1 exacerbation

TDI

Aaron 2007 [11]

12

304 (T 156, T + S 148)

65.9 (8.6)

56

50.3 (27.6)

41.7 (13.3)

Yes

No

Yes

Yes

Baumgartner 2007 [12]

3

428 (A 141, S 144, Pl 143)

62.9 (9.0)

58

NR

40.8 (12.7)

Yes

Yes

Yes

Yes

Beeh 2006 [32]

3

1639 (T 1236, Pl 403)

62.2 (8.7)

76

35.8 (19.5)

45.5 (14.9)

No

No

Yes

No

Boyd 1997 [33]

4

456 (S 229, Pl 227)

61.5

79

NR

NR

No

No

Yes

Yes

Briggs 2005 [34]

3

653 (T 328, S 325)

64.4 (6.3)

67

55.9 (28.8)

37.7 (12.1)

No

No

Yes

No

Brusasco 2003 [13]

6

1207 (T 402, S 405, Pl 400)

64.2 (8.4)

76

43.8 (23.2)

38.5 (11.8)

Yes

No

Yes

Yes

Calverley 2003 [14]

12

733 (S 372, Pl 361)

63.3 (8.6)

72

43.6 (22.2)

44.3 (13.8)

Yes

No

No

No

Calverley 2007 [15]

12

6184 (S 1521, Pl 1524)

65.0 (8.2)

76

49.0 (27.3)

43.9 (12.5)

Yes

No

No

No

Campbell 2005 [16]

6

442 (F 225, Pl 217)

60

68

37

53.8

Yes

No

Yes

No

Casaburi 2000 [35]

3

470 (T 279, Pl 191)

65.2 (8.8)

65

62.9 (32.0)

39.0 (13.9)

No

No

Yes

No

Casaburi 2002 [17]

12

921 (T 550, Pl 371)

65.0 (9.0)

65

61.0 (30.5)

38.6 (13.9)

Yes

Yes

Yes

No

Chan 2007[18]

12

913 (T 608, Pl 305)

66.8 (8.8)

60

50.4 (23.9)

39.4 (13.5)

Yes

Yes

Yes

No

Chapman 2002 [19]

6

408 (S 201, Pl 207)

NR

64

38

45

Yes

Yes

Yes

No

Covelli 2005 [36]

3

196 (T 100, Pl 96)

64.6 (9.0)

58

65.5 (33.4)

39.4 (13.4)

No

No

Yes

No

Dahl 2001 [20]

6

392 (F 192, Pl 200)

63.5 (8.4)

77

41.8

45.0 (12.7)

Yes

Yes

Yes

No

Donohue 2002 [21]

6

623 (T 209, S 213, Pl 201)

64.9 (7.9)

75

47.0 (25.0)

42.3 (9.3)

Yes

Yes

Yes

Yes

Donohue 2008 [37]

12

793 (Af 528, S 265)

64.2 (8.8)

59

NR

38.0 (13.1)

No

No

Yes

No

Dusser 2006 [38]

12

1010 (T 500, Pl 510)

64.8 (9.3)

88

NR

47.9 (12.7)

No

No

Yes

No

Freeman 2007 [39]

3

395 (T 200, Pl 195)

64.9 (9.1)

54

37.4 (17.3)

48.9 (10.6)

No

No

Yes

No

Gross 2008 [22]

3

351 (F 123, Pl 114)

62.7 (8.9)

58

NR

44.5 (12.1)

Yes

Yes

Yes

No

Johansson 2008 [40]

3

224 (T 107, Pl 117)

61.5 (8.3)

48

31.5 (12.1)

73.4 (12.6)

No

No

Yes

No

Jones 1997 [23]

3

189 (S 94, Pl 95)

62.5 (8.0)

79

NR

46.0 (15.0)

Yes

No

No

No

Mahler 1999 [41]

3

411 (S 135, I 133, Pl 143)

63.5 (8.5)

74

60.2 (32.5)

40.0

No

No

Yes

Yes

Moita 2008 [42]

3

311 (T 147, Pl 164)

64.3 (8.6)

95

55.0 (23.6)

41.4 (14.1)

No

No

Yes

No

Niewoehner 2005 [43]

6

1829 (T 914, Pl 915)

67.9 (8.6)

99

68.4 (36.0)

35.6 (12.6)

No

No

Yes

No

Rennard 2009 [24]

12

976 (F 495, Pl 481)

63.0 (9.1)

65

NR

40.1 (11.7)

Yes

Yes

No

No

Rossi 2002 [25]

12

645 (F 214, Pl 220)

62.7

83

NR

47.7

Yes

Yes

Yes

No

Sepracor inc. NCT00250679 2009 [26]

6

296 (F 147, Af 149)

64.7 (8.4)

61

NR

41.0 (12.6)

Yes

No

Yes

Yes

Stahl 2001 [5]

3

121 (F 61, Pl 60)

64

52

NR

33.3

Yes

No

No

No

Stockley 2006 [27]

12

726 (S 316, Pl 318)

62.4 (9.2)

67

39.7 (21.6)

46.0 (14.3)

Yes

Yes

No

No

Tashkin 2008 [28]

6

584 (F 284, Pl 300)

63.4 (9.6)

67

NR

40.4 (12.5)

Yes

Yes

No

No

Tashkin 2008 [29]

12

5993 (T 2987, Pl 3006)

64.5 (8.5)

75

48.7 (28.0)

39.4 (12.0)

Yes

No

Yes

No

Tashkin 2009 [30]

3

255 (T + F 124, T 131)

63.8 (8.6)

66

NR

NR

Yes

Yes

Yes

Yes

Tonnel 2008 [31]

9

554 (T 266, Pl 288)

64.2 (9.9)

86

43.7 (21.9)

46.8 (12.8)

Yes

Yes

Yes

No

van Noord 2000 [44]

3

97 (S 47, Pl 50)

74.0 (6.5)

88

NR

40.3 (10.7)

No

No

Yes

No

Vogelmeier 2008 [45]

6

847 (F 210, T 221, F + T 207, Pl 209)

62.6 (8.8)

78

38.0 (19.7)

51.2 (9.9)

No

No

Yes

No

  1. Data are mean (SD) unless otherwise stated. *time point used in analyses
  2. Af: arformoterol, F: formoterol, FEV1: forced expiratory volume in one second, NR: not reported, Pl: placebo, S: salmeterol, SGRQ: St George's Respiratory Questionnaire, T: tiotropium, TDI: Transition Dyspnea Index